NiSource Inc Common Stock vs Novartis AG — how do they compare? NiSource Inc Common Stock trades at $40.9 (market cap $19.44B), while Novartis AG trades at $143.71 (market cap $268.57B). The key difference: Novartis AG is far larger — about 13.8× NiSource Inc Common Stock's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold NiSource Inc Common Stock for 1 Days and Novartis AG for 82 Days on average.
| NI | NVS | |
|---|---|---|
Market Cap | $19.44B | $268.57B |
Volume | 3,945,959 | 1,532,573 |
Sector | Utilities | Health |
52-Week High | $49.08 | $168.62 |
52-Week Low | $39.00 | $121.80 |
Typical Hold Time | 1 Days | 82 Days |
Enterprise Value | $36.77B | $309.89B |
Dividend Yield | 2.96% | 3.31% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novartis (NVS) trades at $143.22, down 0.04% on the day, near the analyst consensus price target of $146. The stock shows mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company reported strong 2025 revenue of $56.67B and net income of $13.98B, with a robust net margin of 24.67%. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though this follows clinical setbacks in other drug programs.
The outlook is cautiously optimistic. The Abogen deal expands the pipeline in autoimmune diseases, a growth area, and analyst consensus leans Hold with a slight upside to the price target. Key risks include integration challenges from recent acquisitions, pipeline volatility after trial failures, and investor scrutiny over M&A strategy. Earnings momentum is mixed, with a recent beat in Q2 but a miss in Q1, requiring consistent execution to justify current valuations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
NiSource is an energy holding company whose regulated subsidiaries provide natural gas and electricity services. Its business is organized around gas distribution and electric operations in the United States.
Read more on NI →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →